Prescient Therapeutics Limited (ASX:PTX)

Australia flag Australia · Delayed Price · Currency is AUD
0.0550
-0.0050 (-8.33%)
Mar 9, 2026, 3:58 PM AEST
30.95%
Market Cap 57.83M
Revenue (ttm) 4.27M
Net Income (ttm) -8.86M
Shares Out 1.05B
EPS (ttm) -0.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 474,204
Average Volume 1,339,393
Open 0.0580
Previous Close 0.0600
Day's Range 0.0540 - 0.0590
52-Week Range 0.0380 - 0.1250
Beta 0.19
RSI 35.27
Earnings Date Feb 26, 2026

About Prescient Therapeutics

Prescient Therapeutics Limited, a clinical stage oncology company, develops drugs for the treatment of haematological and solid cancers in Australia. Its lead drug candidate is PTX-100, a first in class targeted therapy which can disrupt the RAS family pathway by inhibiting the prenylation action of the enzyme GGT-1. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. Prescient Therapeutics Limited was incorporated in 1986 and is based in Melbourne, Australia. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1986
Employees 3
Stock Exchange Australian Securities Exchange
Ticker Symbol PTX
Full Company Profile

Financial Performance

In fiscal year 2025, Prescient Therapeutics's revenue was 4.36 million, an increase of 17.35% compared to the previous year's 3.71 million. Losses were -7.32 million, -11.11% less than in 2024.

Financial Statements

News

Prescient Therapeutics Limited (PSTTF) Discusses EMA Orphan Drug Designation and Clinical Progress of PTX-100 for CTCL Transcript

Prescient Therapeutics Limited (OTC:PSTTF) Discusses EMA Orphan Drug Designation and Clinical Progress of PTX-100 for CTCL November 24, 2025 11:00 PM...

3 months ago - Seeking Alpha